120 related articles for article (PubMed ID: 35768143)
1. FDA approves new agent for the treatment of metastatic prostate cancer.
BJU Int; 2022 Jul; 130(1):3-4. PubMed ID: 35768143
[No Abstract] [Full Text] [Related]
2. FDA approves new combined treatment for advanced prostate cancer.
Cancer; 2023 Dec; 129(24):3841-3842. PubMed ID: 38102101
[No Abstract] [Full Text] [Related]
3. FDA approves prostate cancer treatment that inhibits testosterone synthesis.
Thompson CA
Am J Health Syst Pharm; 2011 Jun; 68(11):960. PubMed ID: 21593221
[No Abstract] [Full Text] [Related]
4. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
5. FDA approves prostate cancer "vaccine".
Tanne JH
BMJ; 2010 May; 340():c2431. PubMed ID: 20442242
[No Abstract] [Full Text] [Related]
6. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
BJU Int; 2021 Aug; 128(2):127-130. PubMed ID: 34318983
[No Abstract] [Full Text] [Related]
7. FDA approves 11C-choline for PET in prostate cancer.
J Nucl Med; 2012 Dec; 53(12):11N. PubMed ID: 23203247
[No Abstract] [Full Text] [Related]
8. FDA Approves New
J Nucl Med; 2022 Feb; 63(2):26N. PubMed ID: 35101932
[No Abstract] [Full Text] [Related]
9. FDA Approves Ga 68 PSMA-11 for Prostate Cancer Imaging.
Masters SC; Hofling AA; Gorovets A; Marzella L
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):27-28. PubMed ID: 33857629
[No Abstract] [Full Text] [Related]
10. The FDA Approves PSMAtargeted Drug for PET Imaging in Men with Prostate Cancer.
BJU Int; 2021 Mar; 127(3):267-268. PubMed ID: 33630419
[No Abstract] [Full Text] [Related]
11. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
McBride D
ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
[No Abstract] [Full Text] [Related]
12. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
[No Abstract] [Full Text] [Related]
13. FDA approves new PSA test.
Harv Mens Health Watch; 2012 Sep; 17(2):8. PubMed ID: 23050286
[No Abstract] [Full Text] [Related]
14. New Drug for Prostate Cancer.
Aschenbrenner DS
Am J Nurs; 2019 Nov; 119(11):21. PubMed ID: 31651492
[No Abstract] [Full Text] [Related]
15. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.
Kaplan-Marans E
J Urol; 2022 Jan; 207(1):242-243. PubMed ID: 34633229
[No Abstract] [Full Text] [Related]
16. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Reply.
Zhang KW; Guha A
J Urol; 2022 Jan; 207(1):243. PubMed ID: 34633228
[No Abstract] [Full Text] [Related]
17. Prostate cancer drugs could pose risk to heart health. FDA reviewing safety of anti-hormone treatments due to links with heart disease and diabetes.
Heart Advis; 2010 Aug; 13(8):5. PubMed ID: 22792575
[No Abstract] [Full Text] [Related]
18. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
19. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
[TBL] [Abstract][Full Text] [Related]
20. Apalutamide (Erleada) for prostate cancer.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
